普拉克索联合阿戈美拉汀治疗帕金森病患者睡眠障碍的临床观察  

Clinical observation of pramipexole combined with agomelatine treatment of sleep disorders in patients with Parkinson's disease

作　　者：李文婷[1] 张平[1] 陈勇军[1] 刘贵香[1] 

机构地区：[1]南华大学附属南华医院神经内科,衡阳421002

出　　处：《北方药学》2018年第1期12-13,共2页Journal of North Pharmacy

摘　　要：目的:观察普拉克索联合阿戈美拉汀治疗帕金森病患者睡眠障碍的临床疗效及安全性。方法:将60例符合纳入标准的帕金森病患者随机分为对照组和治疗组,每组各30例,疗程12周,采用匹兹堡睡眠质量指数(Pittsburgh sleep quality index,PQSI)、爱泼沃斯思睡量表(Epworth sleepiness scale,ESS)评定治疗效果;采用药品不良反应量表(Treatment emergent symptom scale,TESS)评价药物安全性。结果:(1)两组治疗后PSQI、ESS评分较治疗前明显改善;(2)治疗后,治疗组较对照组PQSI和ESS评分明显降低;(3)治疗后,治疗组总有效率优于对照组;(4)两组不良反应轻微。结论:普拉克索联合阿戈美拉汀治疗帕金森病患者睡眠障碍是安全有效的。Objective： To observe the clinical efficacy and safety of pramipexole combined with agomelatine treatment of sleep disorders in patients with Parkinson＇ disease. Methods： 60 patients with Parkinson＇s disease were randomly divided into control group and treatment group, 30 cases in each group. The treatment lasted for 12 weeks. Using the PSQI and ESS to assess the effectiveness of the treatment; Drug safety was assessed using the TESS. Results： ① The scores of PSQI and ESS in the two groups were significantly improved compared with those before treatment; ②After treatment, the scores of PQSI and ESS in the treatment group were significantly lower than that in the control group ; ③After treatment, the total effective rate of the treatment group is better than that of the control group; ④ The adverse drug reaction were slight in the two groups.Conclusion： Pramipexole combined with agomelatine treatment of sleep disorders in patients with Parkinsou＇s disease is safe and effective.

关 键 词：普拉克索 阿戈关拉汀 帕金森病 睡眠障碍 

分 类 号：R742.5[医药卫生—神经病学与精神病学]